Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of nifedipine GITS plus candesartan in essential hypertension
2009-017077-37Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nifedipine and candesartan cilexetil in essential hypertension (4 arms), sponsored by Bayer. Primary endpoint: Change from baseline in mean seated diastolic blood pressure at Week 8. Started Feb 2011; status: completed.
02
Drugs
nifedipinecandesartan cilexetil
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2009-017077-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017077-37.